Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registry--The EXCITING-ILD Registry

Michael Kreuter, Felix J F Herth, Margarethe Wacker, Reiner Leidl, Andreas Hellmann, Michael Pfeifer, Jürgen Behr, Sabine Witt, Dagmar Kauschka, Marcus Mall, Andreas Günther, Philipp Markart, Michael Kreuter, Felix J F Herth, Margarethe Wacker, Reiner Leidl, Andreas Hellmann, Michael Pfeifer, Jürgen Behr, Sabine Witt, Dagmar Kauschka, Marcus Mall, Andreas Günther, Philipp Markart

Abstract

Despite a number of prospective registries conducted in past years, the current epidemiology of interstitial lung diseases (ILD) is still not well defined, particularly regarding the prevalence and incidence, their management, healthcare utilisation needs, and healthcare-associated costs. To address these issues in Germany, a new prospective ILD registry, "Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases" (EXCITING-ILD), is being conducted by the German Centre for Lung Research in association with ambulatory, inpatient, scientific pulmonology organisations and patient support groups. This multicentre, noninterventional, prospective, and observational ILD registry aims to collect comprehensive and validated data from all healthcare institutions on the incidence, prevalence, characteristics, management, and outcomes regarding all ILD presentations in the real-world setting. Specifically, this registry will collect demographic data, disease-related data such as ILD subtype, treatments, diagnostic procedures (e.g., HRCT, surgical lung biopsy), risk factors (e.g., familial ILD), significant comorbidities, ILD managements, and disease outcomes as well as healthcare resource consumption. The EXCITING-ILD registry will include in-patient and out-patient ILD healthcare facilities in more than 100 sites. In summary, this registry will document comprehensive and current epidemiological data as well as important health economic data for ILDs in Germany.

Figures

Figure 1
Figure 1
Classification of ILDs. PAP: pulmonary alveolar proteinosis, LAM: lymphangioleiomyomatosis, and PLHC: pulmonary Langerhans cell histiocytosis. Adapted from the American Thoracic Society, European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, Am J Respir Crit Care Med. 2002, and Travis et al. Am J Respir Crit Care Med. 2013 [2, 3].

References

    1. Valeyre D., Duchemann B., Nunes H., Uzunhan Y., Annesi-Maesano I. Interstitial lung diseases. In: Welte T., Annesi-Maesano I., Viegi G., Lundbäck B., editors. Respiratory Epidemiology. chapter 6. Vol. 65. ERS; 2014. (ERS Monograph).
    1. American Thoracic Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine. 2002;165(2):277–304. doi: 10.1164/ajrccm.165.2.ats01.
    1. Travis W. D., Costabel U., Hansell D. M. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine. 2013;188(6):733–748. doi: 10.1164/rccm.201308-1483ST.
    1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015;385(9963):117–171. doi: 10.1016/S0140-6736(14)61682-2.
    1. Raghu G., Collard H. R., Egan J. J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine. 2011;183(6):788–824. doi: 10.1164/rccm.2009-040gl.
    1. Swigris J. J., Olson A. L., Huie T. J., et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. American Journal of Respiratory and Critical Care Medicine. 2011;183(11):1524–1530. doi: 10.1164/rccm.201010-1679oc.
    1. Coultas D. B., Zumwalt R. E., Black W. C., Sobonya R. E. The epidemiology of interstitial lung diseases. American Journal of Respiratory and Critical Care Medicine. 1994;150(4):967–972. doi: 10.1164/ajrccm.150.4.7921471.
    1. Karakatsani A., Papakosta D., Rapti A., et al. Epidemiology of interstitial lung diseases in Greece. Respiratory Medicine. 2009;103(8):1122–1129. doi: 10.1016/j.rmed.2009.03.001.
    1. Xaubet A., Ancochea J., Morell F., et al. Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2004;21(1):64–70.
    1. López-Campos J. L., Rodríguez-Becerra E. Incidence of interstitial lung diseases in the south of Spain 1998–2000: the RENIA Study. European Journal of Epidemiology. 2004;19(2):155–161. doi: 10.1023/b:ejep.0000017660.18541.83.
    1. Musellim B., Okumus G., Uzaslan E., et al. Epidemiology and distribution of interstitial lung diseases in Turkey. The Clinical Respiratory Journal. 2014;8(1):55–62. doi: 10.1111/crj.12035.
    1. Gribbin J., Hubbard R. B., Le Jeune I., Smith C. J. P., West J., Tata L. J. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61(11):980–985. doi: 10.1136/thx.2006.062836.
    1. Kornum J. B., Christensen S., Grijota M., et al. The incidence of interstitial lung disease 1995–2005: a Danish nationwide population-based study. BMC Pulmonary Medicine. 2008;8, article 24 doi: 10.1186/1471-2466-8-24.
    1. Demedts M., Wells A. U., Antó J. M., et al. Interstitial lung diseases: an epidemiological overview. The European Respiratory Journal. 2001;18(32, supplement)
    1. Roelandt M., Demedts M., Callebaut W., et al. Epidemiology of interstitial lung disease (ILD) in flanders: registration by pneumologists in 1992–1994. Working group on ILD, VRGT. Vereniging voor Respiratoire Gezondheidszorg en Tuberculosebestrijding. Acta Clinica Belgica. 1995;50(5):260–268.
    1. Thomeer M., Demedts M., Vandeurzen K. Registration of interstitial lung diseases by 20 centres of respiratory medicine in flanders. Acta Clinica Belgica. 2001;56(3):163–172. doi: 10.1179/acb.2001.026.
    1. Schweisfurth H., Kieslich C., Satake N., et al. How are interstitial lung diseases diagnosed in Germany? Results of the scientific registry for the exploration of interstitial lung diseases (‘fibrosis registry’) of the WATL. Pneumologie. 2003;57(7):373–382. doi: 10.1055/s-2003-40557. (Ger).
    1. Schweisfurth H. Report by the Scientific Working Group for therapy of lung diseases: German fibrosis register with initial results. Pneumologie. 1996;50(12):899–901. (Ger).
    1. ERS. ERS European Lung Whitebook. chapter 22. ERS; 2015. Interstitial lung diseases.
    1. Behr J., Kreuter M., Hoeper M. H., et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry. The European Respiratory Journal. 2015;46(1):186–196. doi: 10.1183/09031936.00217614.
    1. Richeldi L., du Bois R. M., Raghu G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. The New England Journal of Medicine. 2014;370(22):2071–2082. doi: 10.1056/nejmoa1402584.
    1. King T. E., Jr., Bradford W. Z., Castro-Bernardini S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England Journal of Medicine. 2014;370(22):2083–2092. doi: 10.1056/nejmoa1402582.
    1. McCormack F. X., Inoue Y., Moss J., et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. The New England Journal of Medicine. 2011;364(17):1595–1606. doi: 10.1056/nejmoa1100391.
    1. Fioret D., Mannino D., Roman J. In-hospital mortality and costs related to idiopathic pulmonary fibrosis between 1993 and 2008. Chest. 2011;140(4) doi: 10.1378/chest.1117428.1038A
    1. Loveman E., Copley V. R., Colquitt J., et al. The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. Health Technology Assessment. 2015;19(20):1–336. doi: 10.3310/hta19200.
    1. Workman T. A. Community Forum White Papers. Rockville, Md, USA: American Institutes for Research, US Agency for Healthcare Research and Quality; 2013. Engaging patients in information sharing and data collection, the role of patient-powered registries and research networks.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit